Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis

World J Gastroenterol. 2015 May 21;21(19):5985-94. doi: 10.3748/wjg.v21.i19.5985.

Abstract

Aim: To evaluate the effectiveness of probiotic therapy for suppressing relapse in patients with inactive ulcerative colitis (UC).

Methods: Bio-Three tablets, each containing 2 mg of lactomin (Streptococcus faecalis T-110), 10 mg of Clostridium butyricum TO-A, and 10 mg of Bacillus mesentericus TO-A, were used as probiotic therapy. Sixty outpatients with UC in remission were randomly assigned to receive 9 Bio-Three tablets/day (Bio-Three group) or 9 placebo tablets/day (placebo group) for 12 mo in addition to their ongoing medications. Clinical symptoms were evaluated monthly or on the exacerbation of symptoms or need for additional medication. Fecal samples were collected to analyze bacterial DNA at baseline and 3-mo intervals. Terminal restriction fragment length polymorphism and cluster analyses were done to examine bacterial components of the fecal microflora.

Results: Forty-six patients, 23 in each group, completed the study, and 14 were excluded. The relapse rates in the Bio-Three and placebo groups were respectively 0.0% vs 17.4% at 3 mo (P = 0.036), 8.7% vs 26.1% at 6 mo (P = 0.119), and 21.7% vs 34.8% (P = 0.326) at 9 mo. At 12 mo, the remission rate was 69.5% in the Bio-Three group and 56.6% in the placebo group (P = 0.248). On cluster analysis of fecal flora, 7 patients belonged to cluster I, 32 to cluster II, and 7 to cluster III.

Conclusion: Probiotics may be effective for maintaining clinical remission in patients with quiescent UC, especially those who belong to cluster I on fecal bacterial analysis.

Keywords: Cluster analysis; Inflammatory bowel disease; Probiotics; Ulcerative colitis.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bacillus / genetics
  • Bacillus / growth & development
  • Chromatography, High Pressure Liquid
  • Clostridium butyricum / genetics
  • Clostridium butyricum / growth & development
  • Cluster Analysis
  • Colitis, Ulcerative / diagnosis
  • Colitis, Ulcerative / microbiology
  • Colitis, Ulcerative / therapy*
  • Colon / microbiology*
  • DNA, Bacterial / genetics
  • Double-Blind Method
  • Enterococcus faecalis / genetics
  • Enterococcus faecalis / growth & development
  • Feces / microbiology
  • Female
  • Humans
  • Japan
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Probiotics / adverse effects
  • Probiotics / therapeutic use*
  • Recurrence
  • Remission Induction
  • Ribotyping
  • Time Factors
  • Treatment Outcome

Substances

  • DNA, Bacterial